First Western Trust Bank Sells 1,112 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

First Western Trust Bank lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 78,887 shares of the biopharmaceutical company’s stock after selling 1,112 shares during the quarter. First Western Trust Bank’s holdings in Gilead Sciences were worth $6,080,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of GILD. Sanctuary Wealth Management L.L.C. bought a new position in shares of Gilead Sciences in the second quarter worth about $30,000. Steward Financial Group LLC acquired a new stake in Gilead Sciences during the 2nd quarter valued at approximately $31,000. Providence Capital Advisors LLC increased its position in Gilead Sciences by 102.9% during the 2nd quarter. Providence Capital Advisors LLC now owns 424 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 215 shares during the period. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the 1st quarter valued at approximately $36,000. Finally, Venturi Wealth Management LLC acquired a new stake in Gilead Sciences during the 1st quarter valued at approximately $36,000. Institutional investors own 82.33% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total transaction of $400,000.00. Following the transaction, the chief financial officer now directly owns 104,003 shares in the company, valued at approximately $8,320,240. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 17th. The stock was sold at an average price of $80.00, for a total transaction of $400,000.00. Following the completion of the sale, the chief financial officer now directly owns 104,003 shares of the company’s stock, valued at approximately $8,320,240. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Merdad Parsey sold 1,501 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total value of $115,561.99. Following the sale, the insider now directly owns 70,130 shares of the company’s stock, valued at $5,399,308.70. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Leerink Partnrs reissued a “market perform” rating on shares of Gilead Sciences in a research report on Wednesday, October 11th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Gilead Sciences in a research report on Thursday, November 9th. They set a “hold” rating and a $75.00 price objective for the company. HSBC initiated coverage on shares of Gilead Sciences in a research report on Wednesday, September 6th. They set a “reduce” rating and a $71.00 price objective for the company. Royal Bank of Canada reduced their price objective on shares of Gilead Sciences from $78.00 to $77.00 and set a “sector perform” rating for the company in a research report on Tuesday, November 14th. Finally, Truist Financial reaffirmed a “buy” rating and set a $91.00 price objective on shares of Gilead Sciences in a research report on Wednesday, September 6th. One analyst has rated the stock with a sell rating, ten have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences has an average rating of “Hold” and an average price target of $88.22.

Gilead Sciences Stock Down 0.3 %

NASDAQ:GILD traded down $0.19 during trading hours on Monday, hitting $75.26. 2,576,730 shares of the company traded hands, compared to its average volume of 5,756,789. The company has a quick ratio of 1.20, a current ratio of 1.34 and a debt-to-equity ratio of 1.08. The firm’s 50-day simple moving average is $76.82 and its 200-day simple moving average is $77.26. Gilead Sciences, Inc. has a one year low of $72.87 and a one year high of $89.74. The company has a market cap of $93.78 billion, a PE ratio of 16.27, a PEG ratio of 1.00 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.38. Gilead Sciences had a return on equity of 39.30% and a net margin of 21.45%. The business had revenue of $7.05 billion for the quarter, compared to analysts’ expectations of $6.81 billion. During the same period last year, the business earned $1.90 EPS. The business’s revenue was up .1% on a year-over-year basis. Equities analysts predict that Gilead Sciences, Inc. will post 6.76 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 3.99%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 64.38%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.